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Poster Session II 165of the treatment are. The content domain of a patient-reported in-
strument to measure the symptom burden of cGVHD should in-
clude questions about the severity of numerous symptoms and
how those symptoms have interfered with normal functioning.
Symptom burden should be measured longitudinally to capture
changes in symptom burden over time. Clinicians caring for pa-
tients with cGVHD should reduce uncertainty as much as possible
by offering clear explanations and should support patients in appro-
priate efforts at self-care to relieve symptoms.PHARMACY467
CLONAZEPAM PLUS LEVETIRACETAM (CL) FOR THE PREVENTION OF
BUSULFAN-INDUCED SEIZURES: A SINGLE CENTER EXPERIENCE
Bubalo, J.S.1, Kovascovics, T.J.1, Meyers, G.1, Mauro, M.1, Epner, E.1,
Hayes-Lattin, B.1, Deininger, M.1, Curtin, P.T.2, Leis, J.F.3,
Maziarz, R.T.1. 1Oregon Health & Science University Hospital, Port-
land, OR; 2University of California San Diego, San Diego, CA; 3Mayo
Clinic, Phoenix, AZ.
High dose busulfan (.1 mg/kg) used in hematopoietic stem cell
transplant (HSCT) conditioning regimens is associated with a de-
crease in seizure threshold which can result in partial or generalized
seizures in up to 10% of people without a previous seizure history.
Phenytoin is the most frequently used agent to prevent seizures.
Though this is an effective therapy, the frequent side effects and sig-
nificant risk for drug interactions from phenytoin make it a subopti-
mal agent for this purpose. Also there is no preferred anti-seizure
prophylaxis for phenytoin allergic or intolerant patients. A retro-
spective review was performed of a single center experience using
CL in 46 consecutive patients receiving a variety of inpatient and
outpatient busulfan-containing regimens to assess it for side effects
and efficacy. The patients received the CL regimen over a 13month
period beginning July, 2006. Clonazepam 0.5 mg and levetiracetam
500mg where given together orally twice daily, beginning the even-
ing before busulfan therapy initiated until discontinuation on the
morning after the final busulfan dose was given. All patients were
adults, 20 female/26 male, aged 22–75 years, (mean 52, median 56
y/o), weight 54–113 kg (Mean and median 82 kg), with no prior his-
tory of seizures. They received HSCT conditioning regimens con-
taining oral (PO) busulfan 1 mg/kg/dose  12–16 doses, or
intravenous (IV) busulfan 3.2 mg/kg/day  1–3 days as part of the
following regimens: 5 - busulfan (12 mg/kg PO)/melphalan(100
mg/m2)/thiotepa 500 mg/m2), 4 - busulfan (9.6 mg/kg IV)/melpha-
lan(100 mg/m2)/thiotepa 500 mg/m2), 20 - busulfan (16 mg/kg)
PO/cyclophosphamide (120 mg/m2), and 16 - busulfan 3.2 mg/kg
IV/fludarabine (120 mg/m2/TBI (200 cGy). The regimen was com-
pletely successful with no patients experiencing any type of seizure
within 48 hours of their last dose of busulfan. Side effects were mild:
2 patients reporting mild sedation and 1 patient had their levetira-
cetam dose reduced to 250 mg twice daily for confusion. When
compared to the prior 104 patients receiving the same variety of
conditioning regimens with phenytoin anti-seizure prophylaxis,
fewer side effects were seen, with equal anti-seizure benefits and
a limited risk for drug interactions using the CL regimen. The
CL regimen is now the preferred therapy for busulfan seizure pro-
phylaxis for the transplant center.468
METHOTREXATE AND PIPERACILLIN/TAZOBACTAM VERSUS METHO-
TREXATE AND CEFTAZIDIME: A LOOK AT TIME TO ENGRAFTMENT
AND SIDE EFFECT PROFILE DIFFERENCES IN HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS
Hoffmann, P.D., Haight, A.E. Children’s Healthcare of Atlanta, At-
lanta, GA.
Many HSCT patients receive methotrexate for GVHD prophy-
laxis. Commonly, methotrexate is given on days 11, 13, 16, and
variably 111. Most patients develop fever during this time period
and empiric antibiotics are started.In June 2006, our institution’s SOP changed the empiric antibi-
otic for fever from ceftazidime to piperacillin/tazobactam. Penicil-
lin derivatives interact with antineoplastic doses of methotrexate by
competing for renal tubular binding sites. Methotrexate toxicity
may include severe mucositis, marrow suppression, renal dysfunc-
tion, and hepatotoxicity. Smaller doses of methotrexate, like those
used for GVHD prophylaxis, have not been investigated. We eval-
uated side effects in patients who may have prolonged methotrexate
exposure caused by piperacillin/tazobactam co-administration.
We examined 36 patients over two years who receivedmethotrex-
ate for GVHD prophylaxis, comparing patients who received ceph-
alosporins with those receiving piperacillin/tazobactam. The
cephalosporin group included 23 patients (14 females, 9 males),
from July 1, 2005 to June 30, 2006. Average time to engraftment
(the first of three consecutive days with ANC . 500) was 18.25
(range 12–22) days for matched unrelated donor (MUD) trans-
plants, 11.9 (9–20) for matched sibling (MS) transplants, and
16.33 (14–19) for mismatched related transplants; overall average
for this group was 16.04 days to engraft. The piperacillin/tazobac-
tam group included a total of 13 patients (11 males, 2 females), from
July 1, 2006 to June 30, 2007. MUD transplants averaged 20.2 (16–
23) days, and MS transplants 17.4 (15–22); overall average was 18.7
days to engraft. Average days antibiotics overlapped methotrexate
was 6.17 and 5.46 for cephalosporin and piperacillin/tazobactam
groups, respectively. No significant differences in transaminases,
bilirubin, and serum creatinine were noted.
In summary, only a difference in time to engraftment was found,
with the piperacillin/tazobactam group taking 2.66 days longer.
This study is limited by small sample size and potential confounding
variables. Mucositis severity could not be compared in this retro-
spective study, but would be of interest for future studies. Based
on this small, retrospective single institution study, we conclude
that a major interaction between small doses of methotrexate and
piperacillin/tazobactam is not seen.469
HIGH RATE OF REVACCINATION IN ALLOGENEIC AND EARLY AUTOLO-
GOUS STEM CELL TRANSPLANTATION—RESULTS OF A SINGLE CENTER
COMPLIANCE TRACKING SURVEY
West, K., Brown, K., Paplham, P., Privitere, L., Syta, M.,
Battiwalla, M., Smiley, S., McCarthy, P.L. Roswell Park Cancer Insti-
tute, Buffalo, NY.
Background:Hematopoietic stem cell transplants (HSCT) have
increased over the past 25 years. With improving HSCT outcomes,
the number of long-term survivors has grown. HSCT recipients
lose their memory immune response against common vaccine-pre-
ventable infections and suffer from life-threatening late infectious
complications. Revaccination is an important strategy for reducing
the risk of preventable infections after HSCT. Materials and
Methods: After the implementation of an annual post transplant
clinic, compliance with revaccination recommendations of the In-
fectious DiseaseWorking Party of the EBMT (BMT 2005) was an-
alyzed. Initially letters were sent to patients greater than 1 year post
transplant inviting them to visit the clinic. The goal of the annual
clinic was to educate HSCT recipients, identify complications,
and recommend therapy for long-term post-transplant issues. Pa-
tients were encouraged to bring their immunization records to their
appointments. Data were collected from January 2006 until August
2007 utilizing patient histories and computer data base documenta-
tion tools for the clinic. Schedules were generated based on the rec-
ommendations of the Infectious Diseases Working Party of the
EBMT. Results: 42 subjects, 27 autologous and 15 allogeneic, at-
tended annual clinic during this time period. 27 patients had initi-
ated the recommended vaccination schedule and/or elected to
start or continue the re-immunization schedule after attending
the clinic. Fifteen patients declined vaccinations (11 autos and 4 al-
los) for various reasons including time out from transplant (median
10 years), 1 completed recommended series, 1 due to immunosup-
pressive therapy, and 1 with history of adverse reaction to vaccine
excipients. Patients declining full revaccination were encouraged
to maintain standard revaccinations such as yearly influenza shots
and ten year diphtheria/tetanus boosters. There were no toxicities
associated with revaccination. Conclusion: Education and
